

CLAIMS

1. An insulin analogue wherein the 12th, 16th or 26th amino acid of the B chain of human insulin (Val, Tyr or Tyr, respectively) is substituted by another amino acid, such that the analogue is monomeric, and which also comprises a deletion at B1(Phe) and/or B30(Thr).
2. An insulin analogue wherein the 16th or 26th amino acid of the B chain of human insulin (Val, Tyr or Tyr, respectively) is substituted by another amino acid, such that the analogue is monomeric, for therapeutic use.
3. An insulin analogue according to claim 1, wherein the 12th amino acid is substituted by Thr (B12Thr).
4. An insulin analogue according to claim 1 or claim 2, wherein the 16th amino acid is substituted by Ala (B16Ala).
5. An insulin analogue according to claim 1 or claim 2, wherein the 26th amino acid is substituted by Ala (B26Ala).
6. An insulin analogue according to claim 3, which comprises a deletion at B1 (des-B1, B12Thr).
7. An insulin analogue according to claim 3, which comprises a deletion at B30 (des-B30, B12Thr).
8. An insulin analogue according to claim 3, which comprises deletions at B1 and B30 (des-B1, des-B30, B12Thr).
9. An insulin analogue according to claim 4, which comprises a deletion at B1 (des-B1, B16Ala).
10. An insulin analogue according to claim 4, which comprises a deletion at B30 (des-B30, B16Ala).
11. An insulin analogue according to claim 4, which comprises deletions at B1 and B30 (des-B1, des-B30, B16Ala).
12. An insulin analogue according to claim 4, which comprises a deletion at B1 (des-B1, B26Ala).
13. An insulin analogue according to claim 5, which comprises a deletion at B30 (des-B30, B16Ala).
14. An insulin analogue according to claim 5, which comprises deletions at B1 and B30 (des-B1, des-B30, B26Ala).